Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
Completed · Phase 2
Conditions studied: Non-Small Cell Lung Cancer
In brief
MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification \[increase number of gene copies\]). Testing for tumor gene changes can be performed in tumor tissue or blood samples. Patients must have previously received treatment with chemotherapy. The number of patients to be enrolled will depend on how many enrolled patients experience tumor size reduction. MGCD265 will be administered orally, twice daily. The study is designed to evaluate whether the number of patients experiencing tumor size reduction is substantially higher than would be expected with other available treatments.
Key facts
- Study ID
- NCT02544633
- Run by
- Mirati Therapeutics Inc.
- People needed
- 68
- Starts
- 2015-10-01
- Expected to finish
- 2019-01-01
- Last updated by the study team
- 2020-03-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of non-small cell lung cancer
- Metastatic or locally advanced disease
- Prior platinum chemotherapy or immunotherapy
- Test result showing genetic change in MET tumor gene
- At least one tumor that can be measured on a radiographic scan
You may not qualify if…
- Prior treatment with inhibitor of MET or HGF
- Prior positive test for EGFR mutation or ALK gene rearrangement
- Uncontrolled tumor in the brain
Where it is running
- Clearview Cancer Institute — Huntsville, Alabama, United States
- Fowler Family Center for Cancer Care — Jonesboro, Arkansas, United States
- Providence Saint Joseph Medical Center — Burbank, California, United States
- Saint Joseph Heritage Healthcare — Fullerton, California, United States
- University of California San Diego — La Jolla, California, United States
- Loma Linda University Medical Center — Loma Linda, California, United States
- University of California, San Francisco — San Francisco, California, United States
- Innovative Clinical Reseach Institute — Whittier, California, United States
- St. Mary's Regional Cancer Center — Grand Junction, Colorado, United States
- Eastern Connecticut Hematology and Oncology Associates — Norwich, Connecticut, United States
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- Boca Raton Regional Hospital - Eugene M. & Christine E. Lynn Cancer Institute — Boca Raton, Florida, United States
- Sylvester Comprehensive Cancer Center — Deerfield Beach, Florida, United States
- Florida Cancer Specialists — Fort Myers, Florida, United States
- Mount Sinai Medical Center — Miami Beach, Florida, United States
- Memorial Hospital West — Pembroke Pines, Florida, United States
- Florida Cancer Specialists — St. Petersburg, Florida, United States
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois, United States
- Rush University Medical Center — Chicago, Illinois, United States
- NorthShore University HealthSystem — Evanston, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Goshen Center for Cancer Care — Goshen, Indiana, United States
- Mercy Cancer Center — Mason City, Iowa, United States
- Oncology-Hematology Associates, PA — Danville, Kentucky, United States
- University of Alabama at Birmingham — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.